Physician profile
Robert Lembo
NPI 1225490857
$9,931.26
in general payments reported to CMS, 2019-2025
19 companies · $482 in 2025
The $482 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $237 · 2021: $224 · 2022: $8,122 · 2023: $641 · 2024: $102 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $8,096.90 | 2022-2023 | Onyx Frontier |
| Boston Scientific Corporation | $350.65 | 2021-2025 | Accolade Sr |
| Medtronic Vascular, INC. | $345.07 | 2019-2020 | |
| Shockwave Medical, INC | $255.87 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $209.74 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Recor Medical INC | $124.15 | 2025 | Paradise Ultrasound Renal Denervation System |
| Haemonetics Corporation | $101.56 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $99.95 | 2021 | |
| Sanofi-Aventis U.S. LLC | $96.00 | 2021 | |
| Abiomed | $44.23 | 2025 | |
| Chiesi USA, INC. | $40.88 | 2024-2025 | Cleviprex, Kengreal |
| E.R. Squibb & Sons, L.L.C. | $32.24 | 2022-2023 | Camzyos |
| Amgen INC. | $25.25 | 2025 | Repatha |
| Acist Medical Systems, INC. | $24.18 | 2024 | |
| Angiodynamics, INC. | $19.25 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $18.35 | 2023 | Angio-Seal |
| Lexicon Pharmaceuticals, INC. | $17.24 | 2023 | Inpefa |
| Alexion Pharmaceuticals, INC. | $15.48 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lembo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.